Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant/Adjuvant Pembrolizumab + Chemotherapy in NSCLC
NCT05894889Phase 2Active, not recruiting
- Sponsor
- Peking University
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Peking University. Primary endpoints: Pathological Complete Response Rate and Post-treatment proportion of CXCL13+PD1+ CD8 T cells in all CD8 T cells. Started Jan 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05894889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894889.